Blar i NTNU Open på forfatter "Werlenius, Katja"
-
Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells
Wenger, Anna; Werlenius, Katja; Hallner, Alexander; Fredrik Bergh, Thoren; Farahmand, Dan; Tisell, Magnus; Smits, Anja; Rydenhag, Bertil; Jakola, Asgeir Store; Caren, Helena (Peer reviewed; Journal article, 2018)Glioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of less than 15 months, emphasizing the need for better treatments. Immunotherapy as a treatment for improving or aiding the patient’s ... -
Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial
Jakola, Asgeir S.; Werlenius, Katja; Mudaisi, Munila; Hylin, Sofia; Kinhult, Sara; bartek, Jiri Jr.; Salvesen, Øyvind; Carlsen, Sven Magnus; Strandeus, Michael; Lindskog, Magnus; Lofgren, David; Rydenhaug, Bertil; Carstam, Louise; Gulati, Sasha; Solheim, Ole; Bartek, Jiri; Solheim, Tora Skeidsvoll (Journal article; Peer reviewed, 2018)Background: Disulfiram (DSF) is a well-tolerated, inexpensive, generic drug that has been in use to treat alcoholism since the 1950s. There is now independent preclinical data that supports DSF as an anticancer agent, and ... -
Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients with Recurrent Glioblastoma: A Randomized Clinical Trial
Werlenius, Katja; Kinhult, Sara; Solheim, Tora S; Magelssen, Henriette; Löfgren, David; Mudaisi, Munila; Hylin, Sofia; Bartek, Jiri; Strandéus, Michael; Lindskog, Magnus; Rashid, Havyan Bahroz; Carstam, Louise; Gulati, Sasha; Solheim, Ole Skeidsvoll; Salvesen, Øyvind Olav; Jakola, Asgeir Store (Peer reviewed; Journal article, 2023)Importance Disulfiram has demonstrated broad antitumoral effect in several preclinical studies. One of the proposed indications is for the treatment of glioblastoma. Objective To evaluate the efficacy and safety of ... -
Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH- mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden
Heggebø, Liv Cathrine; Borgen, Ida Maria Henriksen; Rylander, Hillevi; Kiserud, Cecilie E.; Nordenmark, Tonje Kristin Haug; Hellebust, Taran Annette Paulsen; Evensen, Morten Egeberg; Gustavsson, Magnus; Ramberg, Christina; Sprauten, Mette; Magelssen, Henriette; Blakstad, Hanne; Moorthy, Janani; Andersson, Karin; Raunert, Ingela; Henry, Thomas; Moe, Cecilie; Granlund, Carin; Goplen, Dorota; Brekke, Jorunn; Johannessen, Tor-Christian Aase; Solheim, Tora S; Marienhagen, Kirsten; Humberset, Øyvind; Bergström, Per; Agrup, Måns; Dahl, Ludvig; Gubanski, Michael; Gojon, Helene; Brahme, Carl-Johan; Rydén, Isabelle; Jakola, Asgeir Store; Vik-Mo, Einar O.; Lie, Hanne Cathrine; Asphaug, Lars; Hervani, Maziar; Kristensen, Ingrid; Rüegg, Corina Silvia; Olsen, Inge Christoffer; Ledal, Rolf J; Degsell, Eskil; Werlenius, Katja; Blomstrand, Malin; Brandal, Petter (Peer reviewed; Journal article, 2023)Abstract Introduction The use of proton therapy increases globally despite a lack of randomised controlled trials demonstrating its efficacy and safety. Proton therapy enables sparing of non-neoplastic tissue from ...